Clinical Trials Sponsored by Clinique Pasteur

Total 1592 results

Sanofi Pasteur, a Sanofi Company

Completed

Safety and Immunogenicity of Fluzone® Quadrivalent and Fluzone® High-Dose, Influenza Vaccines

Influenza | Flu

United States
Sanofi Pasteur, a Sanofi Company

Completed

Long-Term Study of Hospitalized Dengue & Safety in Thai Children Included in a Tetravalent Dengue Vaccine Efficacy Study

Dengue | Dengue Fever | Dengue Hemorrhagic Fever

Thailand
Sanofi Pasteur, a Sanofi Company

Completed

Immunogenicity and Safety of Fluzone® Quadrivalent, Southern Hemisphere 2015 Formulation (Intramuscular Route)

Influenza

Philippines
Sanofi Pasteur, a Sanofi Company

Terminated

Study of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Adacel® in Healthy Subjects

Dengue Fever | Dengue Hemorrhagic Fever

Philippines
Sanofi Pasteur, a Sanofi Company

Completed

Immunogenicity and Safety of Sanofi Pasteur's CYD Dengue Vaccine in Healthy Children and Adolescents in Latin America

Dengue | Dengue Fever | Dengue Hemorrhagic Fever | Dengue Virus

Puerto Rico, Colombia, Mexico, Honduras
Sanofi Pasteur, a Sanofi Company

Completed

Immunogenicity and Safety of a Tetravalent Dengue Vaccine Booster Injection in Subjects Who Previously Completed a 3-dose Schedule

Dengue Fever | Dengue Hemorrhagic Fever

Singapore
Sanofi Pasteur, a Sanofi Company

Completed

Study of a Novel Tetravalent Dengue Vaccine in Healthy Children and Adolescents Aged 9 to 16 Years in Latin America

Dengue | Dengue Fever | Dengue Hemorrhagic Fever

Colombia, Puerto Rico, Brazil, Honduras, Mexico
Sanofi Pasteur, a Sanofi Company

Completed

Sanofi Pasteur Quadrivalent Influenza Vaccine (QIV) Pregnancy Registry

Pregnancy | Influenza

United States
Sanofi Pasteur, a Sanofi Company

Completed

Study of a Candidate Clostridium Difficile Toxoid Vaccine in Healthy Adult Subjects Aged 40 to 75 Years in Japan

Clostridium Difficile Infection

Japan
Sanofi Pasteur, a Sanofi Company

Completed

Descriptive, Post-marketing, Passive Surveillance Safety Study of ADACEL™ Vaccine

Pertussis

United States
Sanofi Pasteur, a Sanofi Company

Completed

A Study of Two Doses of Oral Cholera Vaccine (Shanchol™) in Subjects Aged 1 Year and Older in the Philippines

Cholera

Philippines
Sanofi Pasteur, a Sanofi Company

Completed

Comparative Study of Immunogenicity and Safety of Flu-ID Vaccine Versus Flu-IM Vaccine

Influenza

Belgium, France
Sanofi Pasteur, a Sanofi Company

Completed

A Study of the Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine in Subjects Aged 65 Years and Older

Influenza

United States
Sanofi Pasteur, a Sanofi Company

Completed

Comparison of Purified Vero Rabies Vaccine, Serum Free With Human Diploid Cell Vaccine in Pre-exposure Use

Rabies

United States
Sanofi Pasteur, a Sanofi Company

Completed

Immunogenicity and Safety of Two-Dose Series of Menactra® in Japanese Healthy Adult Subjects

Meningitis | Meningococcal Infections | Meningococcal Meningitis

Japan
Sanofi Pasteur, a Sanofi Company

Completed

REVAXIS® Versus DT Polio® as a Second Booster in 6 Year-old Children

Tetanus | Diphtheria | Poliomyelitis

France
Sanofi Pasteur, a Sanofi Company

Completed

Post Authorisation Safety Study of Triaxis as a 5th Dose in 4-6 Year Old Spanish Children

Diphtheria, Tetanus and Pertussis

Spain
Sanofi Pasteur, a Sanofi Company

Completed

Safety of REPEVAX® Given One Month After REVAXIS®

Healthy Adult

France
ANRS, Emerging Infectious Diseases
Institut Pasteur

Withdrawn

Efficacy and Safety of the Combination Vitamin D With Standard of Care in Egyptian Patients With Untreated Chronic Hepatitis C (ViZIR)

Chronic Hepatitis C

Egypt
Sanofi Pasteur, a Sanofi Company

Completed

Study of SP306 Given Intramuscularly Compared to DT Given Subcutaneously in Japanese Adolescents 11 - 12 Years Old

Pertussis | Tetanus | Diphtheria

Japan
Sanofi Pasteur, a Sanofi Company

Completed

Safety and Immunogenicity of the 2015-2016 Formulation of Fluzone® Quadrivalent (Influenza Vaccine) Among Healthy Children

Influenza

United States
Sanofi Pasteur, a Sanofi Company

Completed

Persistence of Bactericidal Antibodies in Adults Who Received a Booster Dose of Menactra® Approximately 4 Years Earlier

Meningitis | Meningococcal Infections | Meningococcal Meningitis

United States
Sanofi Pasteur, a Sanofi Company

Completed

Study of Two Doses of Menactra® or One Dose of Monovalent Meningococcal Group C Vaccine With Routine Immunizations

Meningitis | Meningococcal Infection

Canada
Sanofi Pasteur, a Sanofi Company

Completed

Regulatory Post-Marketing Surveillance Study for Hepatitis A Vaccine (AVAXIM 160U)

Hepatitis A

Korea, Republic of
Sanofi Pasteur, a Sanofi Company

Completed

Study to Compare Pediacel® to Infanrix®-IPV+Hib When Both Are Co-Administered With Prevenar® in Infants and Toddlers

Pertussis | Tetanus | Diphtheria | Poliomyelitis | Haemophilus Influenzae Type b

France, Poland
Sanofi Pasteur, a Sanofi Company

Completed

Study of Immunogenicity and Safety of a Booster Dose of DTaP-IPV-HB-PRP~T Combined Vaccine in Healthy Turkish Infants

Hepatitis B | Pertussis | Diphtheria | Polio

Turkey
Sanofi Pasteur, a Sanofi Company

Completed

Study of DTaP-IPV-Hep B-PRP~T Combined Vaccine Compared to Infanrix®Hexa in Healthy Peruvian Infants

Hepatitis B | Pertussis | Tetanus | Diphtheria | Haemophilus Influenzae Type b

Peru
Sanofi Pasteur, a Sanofi Company

Completed

Descriptive, Post-marketing, Surveillance Safety Study of Menactra Vaccine

Meningitis | Meningococcal Disease

United States
Sanofi Pasteur, a Sanofi Company

Completed

Evaluation of Responses to Fluzone® in Infants ≥ 6 Months of Age Who Did or Did Not Receive Fluzone® at 2 Months of Age

Influenza

United States
Sanofi Pasteur, a Sanofi Company

Completed

Study of Influenza Vaccine Revaccination in Healthy Adults Previously Vaccinated With Fluzone ID or Fluzone IM

Influenza

United States, Puerto Rico
Sanofi Pasteur, a Sanofi Company

Completed

Post-marketing Evaluation of Reactions Following Receipt of Recommended Adolescent Pertussis Vaccine

Pertussis | Tetanus | Diphtheria | Poliomyelitis

Germany
Sanofi Pasteur, a Sanofi Company

Terminated

Study of a Multi-Antigen Therapeutic Vaccine in Patients With Metastatic Melanoma

Melanoma | Cancer

Canada, United States
Sanofi Pasteur, a Sanofi Company

Completed

Immunogenicity and Safety of ADACEL™ as Fifth Dose in Taiwan

Pertussis | Tetanus | Diphtheria

Taiwan
Sanofi Pasteur, a Sanofi Company

Completed

Study of Fluzone Vaccine Administered by Intradermal Route in Comparison With Standard Fluzone® in Adults

Influenza | Orthomyxoviridae Infection | Myxovirus Infection

United States, Puerto Rico
Sanofi Pasteur, a Sanofi Company

Completed

Immunogenicity of High-dose Inactivated, Split-virion Influenza Vaccine Versus Standard Fluzone Vaccine in the Elderly

Influenza | Orthomyxoviridae Infection | Myxovirus Infection

United States
Sanofi Pasteur, a Sanofi Company

Completed

Persistence of Bactericidal Antibodies in Adolescents and Adults Who Had Received a Single Dose of Menactra® Vaccine

Meningitis | Meningococcal Infections

United States
Sanofi Pasteur, a Sanofi Company

Completed

A Study of 2 Doses of Menactra®, a Meningococcal Conjugate Vaccine in Healthy Toddlers

Measles | Rubella | Mumps | Varicella | Meningococcal Meningitis

United States
Sanofi Pasteur, a Sanofi Company

Completed

Immunogenicity and Safety of Pediatric Vaccines When Administered With Menactra® in Healthy Toddlers

Measles | Rubella | Mumps | Varicella | Meningococcal Meningitis

United States, Puerto Rico
Sanofi Pasteur, a Sanofi Company

Completed

Safety and Immunogenicity of DAPTACEL® as 5th Dose in Children 4 to 6 Years Old After 4 Doses of Pentacel™ or DAPTACEL®

Pertussis | Tetanus | Diphtheria

United States
Sanofi Pasteur, a Sanofi Company

Completed

Phase IV Trial to Collect Safety Data and Sera for Immunogenicity Testing in Healthy Children Given Fluzone® Vaccine

Influenza

United States
Sanofi Pasteur, a Sanofi Company

Completed

Trial to Describe the Safety and Immunogenicity of Fluzone®

Influenza

United States
Sanofi Pasteur, a Sanofi Company

Completed

Study of Menactra® in Healthy Subjects at 9 Months and Concomitantly With Pentacel® at 15 to 18 Months of Age

Pertussis | Tetanus | Diphtheria | Meningitis | Meningococcal Infection | Haemophilus Influenzae Serotype b (Hib)

United States, Puerto Rico
Sanofi Pasteur, a Sanofi Company

Completed

Study of Quadrivalent Influenza Vaccine Among Children

Influenza

United States
Sanofi Pasteur, a Sanofi Company

Completed

Study of Immune Response in Adults and Elderly Subjects Vaccinated With Inactivated Influenza Vaccines

Influenza | Myxovirus Infection | Orthomyxovirus Infections

France
Sanofi Pasteur, a Sanofi Company

Completed

Sanofi Pasteur's Tdap Combined Vaccine as a Booster Versus Local DT Vaccine in Children or Versus Local Td Vaccine in Adolescents and Adults in China.

Pertussis | Tetanus | Diphtheria

China
Sanofi Pasteur, a Sanofi Company

Completed

Study of Intradermal Quadrivalent Influenza Vaccine in Adults Aged 18 Through 64 Years

Influenza

United States
Sanofi Pasteur, a Sanofi Company

Completed

Safety and Immunogenicity Study of ChimeriVax West Nile Vaccine in Healthy Adults (WinVax004)

West Nile Fever

United States
Sanofi Pasteur, a Sanofi Company

Completed

Study of Tetanus and Diphtheria Toxoids Adsorbed Combined With Component Pertussis Vaccine and Inactivated Poliomyelitis

Hepatitis B | Pertussis | Tetanus | Diphtheria | Poliomyelitis

Canada
Sanofi Pasteur, a Sanofi Company

Completed

Study of an Investigational Pneumococcal Vaccine at Three Dose Levels in Healthy Adults

Pneumococcal Infections | Streptococcus Pneumoniae Infections | Pneumococcal Pneumonia

Switzerland
Sanofi Pasteur, a Sanofi Company

Completed

Safety and Immunogenicity of Formulations of Dengue Vaccines in Healthy Flavivirus-Naïve Adults

Dengue Fever | Dengue Hemorrhagic Fever | Dengue Virus | Dengue Diseases

Mexico

3

Subscribe